Clinical Cancer Research, Vol 3, Issue 4 579-585, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro

I Faraoni, M Turriziani, G Masci, L De Vecchis, JW Shay, E Bonmassar and G Graziani
Department of Experimental Medicine and Biochemical Sciences, University of Rome "Tor Vergata," Via di Tor Vergata 135, 00133 Rome, Italy.

Telomerase activity is frequently associated with the malignant phenotype, and it can be considered an almost ubiquitous tumor marker. In this study, we evaluated telomerase activity in telomerase-positive human tumor cell lines exposed in vitro to antineoplastic agents. The results show that drug-induced cell killing of tumor cells is associated with a decline in detectable telomerase activity. The decrease of telomerase activity levels paralleled cell growth impairment evaluated by cell count or by measurement of cell ability to convert tetrazolium salt to colored formazan [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide assay]. The observed telomerase activity remaining after treatment with antineoplastic agents is most likely to reflect activity from the remaining viable cells. When tumor cell lines resistant to the chemotherapeutic agents temozolomide or doxorubicin were treated with these compounds, no decline of telomerase activity or cell growth was observed. The results of the present study indicate that resistance of neoplastic cells to chemotherapeutic agents can be monitored by following telomerase activity. Moreover, the test can be performed with a limited number of neoplastic cells, such as those frequently obtained from tumor biopsies. These findings provide a rationale for developing new in vitro chemosensitivity assays, and detection of telomerase activity may be a novel marker of chemotherapy failure.

This article has been cited by other articles:

				A. M. Burger, F. Dai, C. M. Schultes, A. P. Reszka, M. J. Moore, J. A. Double, and S. Neidle The G-Quadruplex-Interactive Molecule BRACO-19 Inhibits Tumor Growth, Consistent with Telomere Targeting and Interference with Telomerase Function Cancer Res., February 15, 2005; 65(4): 1489 - 1496. [Abstract] [Full Text] [PDF]

				G. Graziani, L. Tentori, I. Portarena, M. Barbarino, G. Tringali, G. Pozzoli, and P. Navarra CRH Inhibits Cell Growth of Human Endometrial Adenocarcinoma Cells via CRH-Receptor 1-Mediated Activation of cAMP-PKA Pathway Endocrinology, March 1, 2002; 143(3): 807 - 813. [Abstract] [Full Text] [PDF]

				Z. Lin, S. Lim, M. A. Viani, M. Sapp, and M. S. Lim Down-Regulation of Telomerase Activity in Malignant Lymphomas by Radiation and Chemotherapeutic Agents Am. J. Pathol., August 1, 2001; 159(2): 711 - 719. [Abstract] [Full Text]

				J. W. Shay, Y. Zou, E. Hiyama, and W. E. Wright Telomerase and cancer Hum. Mol. Genet., April 1, 2001; 10(7): 677 - 685. [Abstract] [Full Text] [PDF]

				Y. Kitagawa, S. Kyo, M. Takakura, T. Kanaya, K. Koshida, M. Namiki, and M. Inoue Demethylating Reagent 5-Azacytidine Inhibits Telomerase Activity in Human Prostate Cancer Cells through Transcriptional Repression of hTERT Clin. Cancer Res., July 1, 2000; 6(7): 2868 - 2875. [Abstract] [Full Text]

				M. Kusumoto, T. Ogawa, K. Mizumoto, H. Ueno, H. Niiyama, N. Sato, M. Nakamura, and M. Tanaka Adenovirus-mediated p53 Gene Transduction Inhibits Telomerase Activity Independent of Its Effects on Cell Cycle Arrest and Apoptosis in Human Pancreatic Cancer Cells Clin. Cancer Res., August 1, 1999; 5(8): 2140 - 2147. [Abstract] [Full Text] [PDF]

				A. Bednarek, A. Shilkaitis, A. Green, R. Lubet, G. Kelloff, K. Christov, and C. M. Aldaz Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors Carcinogenesis, May 1, 1999; 20(5): 879 - 883. [Abstract] [Full Text] [PDF]

				J.-C. Soria, L. R. Gauthier, E. Raymond, C. Granotier, L. Morat, J.-P. Armand, F. D. Boussin, and L. Sabatier Molecular Detection of Telomerase-positive Circulating Epithelial Cells in Metastatic Breast Cancer Patients Clin. Cancer Res., May 1, 1999; 5(5): 971 - 975. [Abstract] [Full Text] [PDF]

				S. E. Holt, D. L. Aisner, J. W. Shay, and W. E. Wright Lack of cell cycle regulation of telomerase activity in human cells PNAS, September 30, 1997; 94(20): 10687 - 10692. [Abstract] [Full Text] [PDF]

				B. Ogretmen, D. Schady, J. Usta, R. Wood, J. M. Kraveka, C. Luberto, H. Birbes, Y. A. Hannun, and L. M. Obeid Role of Ceramide in Mediating the Inhibition of Telomerase Activity in A549 Human Lung Adenocarcinoma Cells J. Biol. Chem., June 29, 2001; 276(27): 24901 - 24910. [Abstract] [Full Text] [PDF]